Pharmacy News

  • Kal Sundaram Appointed to Taro’s Board of Directors as Chairman
    HAWTHORNE, N.Y.–(BUSINESS WIRE)–Taro Pharmaceutical Industries Ltd. (“Taro,” NYSE: TARO) announced today that Mr. Dilip Shanghvi has resigned, effective today, as Chairman and a member of Taro’s Board of Directors (“Board”) in order to focus on other growth priorities within the Sun Pharmaceutical Industries Ltd. (“Sun Pharma,” Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) group and Mr. Kalyanasundaram Subramanian, known in industry circles as Kal Sundaram, has been appoint
  • ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2012 Financial Results
    WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 27, 2012, to discuss ImmunoGen’s financial results for the three-month period ended March 31, 2012 – the third quarter of the Company’s 2012 fiscal year. Management also will provide an update on the Company. To access the live call by phone, dial 913-312-13
  • Vertex Advances INCIVEK™ (telaprevir) and Broad Portfolio of Medicines in Development With Goal of Further Expanding and Improving Treatment for People With Hepatitis C
    BARCELONA, Spain–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from a retrospective subanalysis of the Phase 2 PROVE 2 study that showed that 100 percent (12/12) of patients with the IL28B CC genotype who were new to treatment achieved a viral cure (sustained viral response, or SVR) with a total of 12 weeks of treatment with INCIVEK™ (telaprevir) tablets, pegylated-interferon and ribavirin. These data support Vertex’s ongoing Phase 3b study that is eva
  • Cubist Pharmaceuticals Reports First Quarter 2012 Financial Results
    LEXINGTON, Mass.–(BUSINESS WIRE)–Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced results for the first quarter ended March 31, 2012. The Company will host a conference call and webcast today at 5:00 p.m. ET (details below). Financial highlights for the first quarter of 2012 (unaudited): Total net revenues grew 30% to $211.7 million compared to $162.5 million in the same period in 2011. Total net product revenues for CUBICIN® (daptomycin for injection) increased 22% to $197.4 millio
  • Merck Wins Another FOSAMAX® (alendronate sodium) State Court Trial
    WHITEHOUSE STATION, N.J.–(BUSINESS WIRE)–Merck, known outside the United States and Canada as MSD, today said a state court jury in New Jersey found in its favor in the Sessner v. Merck case, rejecting the claims of a woman who blamed her jaw-related problems on her FOSAMAX use. “We believe the evidence showed the company acted properly, and that FOSAMAX did not cause the plaintiff’s dental and jaw problems,” said Christy Jones of Butler, Snow, O’Mara, Stevens & Cannada PLLC, outside couns
  • Research and Markets: Myelodysplastic Syndrome – Pipeline Review, H1 2012
    DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/aee897ba/myelodysplastic_sy) has announced the addition of Global Markets Direct’s new report “Myelodysplastic Syndrome – Pipeline Review, H1 2012″ to their offering. Summary Global Markets Direct’s, ‘Myelodysplastic Syndrome – Pipeline Review, H1 2012′, provides an overview of the Myelodysplastic Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Myelodysplas
  • Scientists Report that Process of Converting Non-Beating Heart Cells into Functional, Beating Heart Cells is Enhanced Using Thymosin Beta 4 in Conjunction with Gene Therapy
    ROCKVILLE, Md.–(BUSINESS WIRE)–RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) announced today that scientists at the Gladstone Institute of Cardiovascular Disease, University of California, San Francisco, have published new animal data in the current issue of Nature showing that the process of converting non-beating heart cells (which normally form scar tissue after a heart attack), into functional, beating heart muscle cells can be enhanced using Th
  • Research and Markets: What Do Patients Think of Health Apps? is a Report that Contains Results from 100 Patient Groups from 21 Countries
    DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/232d40db/what_do_patients_t) has announced the addition of the “What Do Patients Think of Health Apps?” report to their offering. Health apps are a technological revolution. They act as a powerful resource to help the patients in whom you are interested manage their medical condition, treatment, and care. Health apps remind patients to take their treatment properly, ensuring that medicines work to best effe
  • DiaGenic ASA: Notification of Trade among Primary Insider
    OSLO, Norway–(BUSINESS WIRE)–Regulatory News: On 18 April 2012 mandatory notification of trade among primary insider Praveen Sharma of DiaGenic ASA (OSE:DIAG) took place. Capveen AS, which is controlled by Sharma, has sold 266,213 shares to Praveen Sharma at NOK 2.45 per share. After this transaction, Capveen AS holds no shares in DiaGenic and Praveen Sharma holds 515,290 shares in DiaGenic in addition to 16.000 share options. Sharma has increased his exposure in DiaGenic ASA by this transacti

Digest powered by RSS Digest


Advertisement

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>